Literature DB >> 823065

Studies of diabetic nephropathy in animals and man.

S M Mauer, M W Steffes, A F Michael, D M Brown.   

Abstract

Animal models of diabetes mellitus allow for the manipulation of the metabolic state and the performance of experiments that may shed light on the pathogenesis of diabetic nephropathy. Rats with long-standing chemically induced diabetes develop glomerular mesangial thickening and immunoglobulin and complement deposition. These glomerular changes are reversible on the transplantation of a kidney from a diabetic rat into a normal host and on cure of the diabetic state by pancreatic islet transplantation. Conversely, diabetic renal changes develop in normal kidneys transplanted into diabetic rats (within tow to four months) and humans (within two years). These studies suggest that nephropathy results from the diabetic state. The mesangium is thickened in diabetic rats, mice, and humans. In rats, mesangial function is the processing of macromolecules localized therein is disturbed in areas of mesangial pathology. The finding that glomerulopathy is accelerated in uninephrectomized diabetic rats and is retarded in rat kidneys "protected" by narrowing of the renal artery suggests that alterations in glomerular blood flow are related to the pathogenesis of diabetic glomerular damage. Marked hyperglycemia in animals and man leads to "glycogen nephrosis," which affects the distal tubule at the level of the macula densa of the juxtaglomerular apparatus (JGA). This could lead to disturbance of JGA blood pressure regulation. Disturned mesangial function may result from failure of macula densa cells to process macromolecules that have reached that site from the mesangium.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 823065

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  22 in total

1.  Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor.

Authors:  G Triolo; E Giardina; D Casiglia; G Scarantino; G D Bompiani
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

2.  Pathogenesis of diabetic microangiopathy.

Authors: 
Journal:  Br Med J       Date:  1977-06-18

Review 3.  Pancreas and islet transplantation. I. Experimental studies.

Authors:  D E Sutherland
Journal:  Diabetologia       Date:  1981-03       Impact factor: 10.122

4.  Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. The mesangial regions.

Authors:  R Rasch
Journal:  Diabetologia       Date:  1979-10       Impact factor: 10.122

5.  Comparison of whole pancreas and pancreatic islet transplantation in controlling nephropathy and metabolic disorders of diabetes.

Authors:  M J Orloff; C Macedo; A Macedo; G E Greenleaf
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

Review 6.  Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms.

Authors:  Stephen Tonna; Assam El-Osta; Mark E Cooper; Chris Tikellis
Journal:  Nat Rev Nephrol       Date:  2010-04-27       Impact factor: 28.314

7.  Evaluation of the presence of circulating immune complexes and their relationship to glomerular IgG deposits in streptozotocin-induced diabetic rats.

Authors:  C K Abrass
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

8.  Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy.

Authors:  T Yamamoto; T Nakamura; N A Noble; E Ruoslahti; W A Border
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  The cochlea of the spontaneously diabetic mouse. II. Electron microscopic observations of non-obese diabetic mice.

Authors:  S Nakae; M Tachibana
Journal:  Arch Otorhinolaryngol       Date:  1986

Review 10.  The case for control in diabetes mellitus.

Authors:  M B Davidson
Journal:  West J Med       Date:  1978-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.